intron-a
merck sharp & dohme (new zealand) limited - interferon alfa-2b 6 miu/ml; - solution for injection - 6 miu/ml - active: interferon alfa-2b 6 miu/ml excipient: dibasic sodium phosphate disodium edetate dihydrate metacresol monobasic sodium phosphate monohydrate polysorbate 80 sodium chloride water for injection
pegatron combination therapy peginterferon alfa-2b (rbe) 150 microgram powder for injection/capsule/diluent composite pack
merck sharp & dohme australia pty ltd - peginterferon alfa-2b,ribavirin -
pegatron combination therapy peginterferon alfa-2b (rbe) 120 microgram powder for injection/capsule/diluent composite pack
merck sharp & dohme australia pty ltd - peginterferon alfa-2b,ribavirin -
pegatron combination therapy peginterferon alfa-2b (rbe) 100 microgram powder for injection/capsule/diluent composite pack
merck sharp & dohme australia pty ltd - peginterferon alfa-2b,ribavirin -
pegatron combination therapy peginterferon alfa-2b (rbe) 80 microgram powder for injection/capsule/diluent composite pack
merck sharp & dohme australia pty ltd - peginterferon alfa-2b,ribavirin -
pegatron combination therapy peginterferon alfa-2b (rbe) 50 microgram powder for injection/capsule/diluent composite pack
merck sharp & dohme australia pty ltd - peginterferon alfa-2b,ribavirin -
roferon-a inferferon alfa-2a 3 million iu/0.5ml injection pre-filled syringe
roche products pty ltd - interferon alfa-2a -
alferon- interferon alfa-n3 injection
aim immunotech inc - interferon alfa-n3 (unii: 47bpr3v3mp) (interferon alfa-n3 - unii:47bpr3v3mp) - interferon alfa-n3 5000000 [arb'u] in 1 ml
pegatron combination therapy
merck sharp & dohme (new zealand) limited - peginterferon alfa-2b 100ug; ribavirin 200mg; - combination - 200mg+100µg(clearclick) - active: peginterferon alfa-2b 100ug excipient: dibasic sodium phosphate monobasic sodium phosphate dihydrate polysorbate 80 sucrose water for injection active: ribavirin 200mg excipient: croscarmellose sodium gelatin lactose monohydrate magnesium stearate microcrystalline cellulose sodium laurilsulfate tekprint blue sb-6018 titanium dioxide - pegatron combination therapy is indicated for the treatment of na?ve, relapse and non-responder patients with chronic hepatitis c (see clinical trials). patients must be 18 years of age or older and have compensated liver disease. pegatron combination therapy is also indicated for the treatment of patients with chronic hepatitis c who are co-infected with clinically stable hiv. interferon alfa monotherapy (including peg-intron) is indicated mainly in case of intolerance or contraindication to ribavirin. rebetol capsules must not be used alone because ribavirin is not effective as monotherapy in the treatment of hepatitis c. pegatron combination therapy is indicated for the treatment of chronic hepatitis c in children and adolescents with a bodyweight of nlt 27 kg with compensated liver disease and who have not received previous interferon treatment.
pegatron combination therapy
merck sharp & dohme (new zealand) limited - peginterferon alfa-2b 120ug; ribavirin 200mg; - combination - 200mg+120µg(clearclick) - active: peginterferon alfa-2b 120ug excipient: dibasic sodium phosphate monobasic sodium phosphate dihydrate polysorbate 80 sucrose water for injection active: ribavirin 200mg excipient: croscarmellose sodium gelatin lactose monohydrate magnesium stearate microcrystalline cellulose sodium laurilsulfate tekprint blue sb-6018 titanium dioxide - pegatron combination therapy is indicated for the treatment of na?ve, relapse and non-responder patients with chronic hepatitis c (see clinical trials). patients must be 18 years of age or older and have compensated liver disease. pegatron combination therapy is also indicated for the treatment of patients with chronic hepatitis c who are co-infected with clinically stable hiv. interferon alfa monotherapy (including peg-intron) is indicated mainly in case of intolerance or contraindication to ribavirin. rebetol capsules must not be used alone because ribavirin is not effective as monotherapy in the treatment of hepatitis c. pegatron combination therapy is indicated for the treatment of chronic hepatitis c in children and adolescents with a bodyweight of nlt 27 kg with compensated liver disease and who have not received previous interferon treatment.